ATTOAttovia Therapeutics, Inc.vs its industry peers
A metric-by-metric comparison of Attovia Therapeutics, Inc. against SIC 2836 — valuation, growth, profitability, quality and total return, with each figure's rank within the peer group. Every value is Go-computed from SEC filings and delayed prices; ranks are sorted positions within the group only — descriptive, not advice.
| Company | Market cap | P/E (TTM) | P/B | P/S | Revenue growth (YoY) | Earnings growth (YoY) | EBIT margin | ROE | ROIC | Piotroski F | 1y total return | Dividend yield |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ATTOThis | $704M#8 | — | — | — | — | — | — | — | — | — | 268.3%#1 | — |
| INBX | $1.0B#1 | — | — | 802.7x#4 | 550.0%#1 | -108.3%#6 | -10386.5%#4 | — | — | — | — | — |
| CGEM | $958M#2 | — | 2.3x#3 | — | -100.0%#5 | -31.2%#5 | — | -53.8%#3 | — | — | — | — |
| ODTX | $933M#3 | — | 2.2x#2 | — | — | — | — | 0.0%#1 | — | — | — | — |
| GLUE | $905M#4 | — | 1.9x#1 | 7.3x#1 | 63.5%#3 | 46.9%#1 | -43.8%#1 | -7.9%#2 | — | — | — | — |
| MGTX | $898M#5 | 10.7x#1 | — | 11.0x#2 | 144.6%#2 | 22.7%#2 | -130.2%#2 | — | — | — | — | — |
| PRME | $840M#6 | — | 21.1x#5 | 181.3x#3 | 55.3%#4 | -2.7%#4 | -4498.1%#3 | -505.3%#5 | — | — | — | — |
| SANA | $751M#7 | — | 4.9x#4 | — | — | 8.5%#3 | — | -158.0%#4 | — | — | — | — |
Peer set: US filers sharing this company's SEC industry classification (SIC 2836). SIC is coarse — conglomerates and multi-segment companies map imperfectly. Values from SEC filings + delayed prices; ranks are within-group positions only. Market cap, P/E, P/B, P/S, 1y total return and dividend yield are computed from each member's latest snapshot price when the table is built (see as-of; snapshot prices can lag) — not live. Some peers are still being computed, so this table covers part of the group and ranks are within the rows shown; it fills in shortly. This table timed out mid-build, so it covers part of the group; ranks are within the rows shown and it fills in shortly. Table built 2026-11-02.
Source: SEC XBRL filings + delayed prices · ranks are within-group positions · For reference only · Not investment advice